Preventing UTIs with Cranberry? It is possible with MonoSelect® Macrocarpon

Cranberry products have been used for several decades to prevent urinary tract infections (UTIs). Recently a Cochrane review has pointed out the mechanism underlying cranberry activity: the compounds known as Proanthocyanidins (PACs) interfere with the adhesion of bacteria, making it more difficult for them to cause an infection.

MonoSelect® Macrocarpon is a clinically tested supplement that helps prevent UTis thanks to its important content in PACs and the enteric coating that avoids the degradation by stomach acids. 

Cranberry PACs to prevent UTIs

Does cranberry help prevent Urinary Tract Infections (UTIs)? The fifth update of a Cochrane review published in May 2023 finally said yes.

The Cochrane meta-analysis involved as much as 50 clinical trials, overall suggesting that cranberry reduces the number of UTIs in women with recurrent UTIs, in children with UTIs and in people susceptible to UTIs.

Moreover, the review identifies cranberry’s Proanthocyanidins (PACs) as key compounds in preventing certain bacteria, such as E. coli, from adhering to the walls of the urinary tract, thus reducing their proliferation and the risk of infection.

A cranberry-based prophylaxis against UTI can be particularly favorable also considering a potential reduction in the use of antibiotics aimed at avoiding gut microbiota disruptions which can, in turn, make people more prone to infections.

It is time to move on from cranberry juice

One thing to point out when it comes to natural ingredients is that the formulation of products may play a crucial role. Cranberry juices, encapsuled extracts and thoughtfully engineered tablets with high PAC content cannot be considered as equal sources of PACs. It is really difficult to estimate how much cranberry juice should be drunk in order to take a certain amount of PACs. The same goes for capsules containing a generic cranberry extract.

So, nothing against drinking cranberry juice. It’s tasty and to some extent healthy but if the aim is to prevent UTIs it is better to rely on a more advanced tool with studied efficacy.

Dealing with cranberry, PharmExtracta®’s R&D department applied the same scientific approach as ever: selecting natural compounds that can make a difference and transforming them into a tool to serve wellbeing, by adding specific know-how and pharmaceutical technology.

The result was MonoSelect® Macrocarpon with 200 mg of a highly standardized extract of Vaccinium macrocarpon fruits, standardized to contain 30% PACs and formulated as an enteric-coated tablet.

MonoSelect® Macrocarpon: standardized extract with optimal dosage plus enteric coating equals to clinical results

MonoSelect® Macrocarpon It is based only on cranberry extract but it makes the most of its potential thanks to the following features.

STANDARDIZATION of the EXTRACT: Each tablet contains 200 mg of high-quality extract from Vaccinium macrocarpon (cranberry) fruit standardized to contain 30% of key compound proanthocyanidins (PACs).

OPTIMAL DOSAGE: the 200 mg/tablet of cranberry extract with guaranteed 30% PACs exhibits with proven dose/efficacy ratio as shown in a big clinical trial.

ENTERIC COATING: The tablets of MonoSelect® Macrocarpon are formulated with an enteric coating that helps protect the cranberry extract from degradation or inactivation by stomach acid, ensuring that its potency is maintained until it reaches the small intestine. When cranberry extract is released in the small intestine (the primary site of nutrient absorption in the digestive system) it encounters a higher pH environment compared to the acidic conditions of the stomach. This higher pH in the intestine is more favorable for the absorption of PACs and for their better uptake into the bloodstream. Overall, by releasing cranberry extract in the intestine, the goal is to enhance its bioavailability and maximize its potential benefits.